Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
Vertex will pick up an FDA-approved oral therapy for acromegaly and a phase 3 drug to treat CAH.
read more
A rolling NDA submission for treatment-resistant depression with the FDA is underway.
read more
The company used AI to prioritize the novel target as well as to generate and optimize the small molecule.
read more
The orally-available compound could provide an alternative to conventional glucocorticoids, the current standard of care.
read more
The partners have received a third CRL for their rivoceranib-camrelizumab combo in hepatocellular carcinoma.
read more
The selective TLR 7/8 inhibitor could become the first approved therapy for cutaneous manifestations of lupus.
read more
The tablets were granted accelerated approval in China and U.S. for locally advanced/metastatic NSCLC with EGFR exon20ins.
read more
Lipfendra reduced LDL-C by more than 50%, including in patients with HeFH.
read more
The deal gives Lilly a pipeline of rapid-acting neuroplastogens.
read more
The strategic investment expands Natoli’s capabilities while ensuring uninterrupted service for customers worldwide.
read more
GSK picked up the experimental cough drug in 2023 when it paid $2 billion to acquire Bellus Health.
read more
Zasocitinib was able to clear or almost clear scalp psoriasis in 75% of trial patients.
read more
The PK activator was not sufficiently different from others in its class to continue development.
read more
Through the deal, Bain will gain access to certain international markets, particularly MENA and China.
read more
Simtriyo is the first norepinephrine, dopamine and serotonin reuptake inhibitor to treat ADHD.
read more